Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.2% – Should You Sell?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) dropped 5.2% during mid-day trading on Monday . The company traded as low as $25.53 and last traded at $25.60. Approximately 179,460 shares were traded during trading, a decline of 39% from the average daily volume of 291,805 shares. The stock had previously closed at $27.00.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of recent research reports. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 price objective for the company. Guggenheim boosted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, September 15th. JPMorgan Chase & Co. boosted their price objective on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 18th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $33.83.

Maze Therapeutics Stock Performance

The business’s 50 day moving average is $17.06 and its two-hundred day moving average is $13.17.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.02.

Insider Buying and Selling

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently bought and sold shares of the stock. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the 1st quarter worth $66,874,000. Frazier Life Sciences Management L.P. lifted its stake in Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares in the last quarter. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics in the 1st quarter worth $45,362,000. Matrix Capital Management Company LP purchased a new stake in Maze Therapeutics in the 1st quarter worth $27,373,000. Finally, Alphabet Inc. purchased a new stake in Maze Therapeutics in the 1st quarter worth $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.